BRPI0409733A - derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animais - Google Patents
derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animaisInfo
- Publication number
- BRPI0409733A BRPI0409733A BRPI0409733-5A BRPI0409733A BRPI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine derivative
- disorder
- crth2
- diseases
- activity
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 201000010099 disease Diseases 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 4
- 150000003230 pyrimidines Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 abstract 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 229940124003 CRTH2 antagonist Drugs 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 102000011652 Formyl peptide receptors Human genes 0.000 abstract 1
- 108010076288 Formyl peptide receptors Proteins 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004241 Th2 cell Anatomy 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010052568 Urticaria chronic Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000024376 chronic urticaria Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 206010024378 leukocytosis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"DERIVADO DE PIRIMIDINA, SUA FORMA TAUTOMéRICA OU ESTEREOISOMéRICA, OU UM SEU SAL , éSTER OU PRó-DROGA, MEDICAMENTO, USO DE UM COMPOSTO, E, PROCESSO PARA CONTROLAR UM DISTúRBIO OU DOENçA ASSOCIADO COM A ATIVIDADE CRTH2 EM HUMANOS E ANIMAIS". A presente invenção refere-se a um derivado de pirimidina de Fórmula (I) e seus sais, que são úteis como um ingrediente ativo de preparações farmacêuticas. O derivado de pirimidina da presente invenção tem excelente atividade antagonista CRTH2 (receptor quimioatraente acoplado proteína-G, expresso nas células Th2) e pode ser usado para a profilaxia e tratamento de doenças associadas com a atividade CRTH2, em particular para o tratamento de doenças alérgicas, tais como asma, rinite alérgica, dermatite atópica e conjuntivite alérgica; doenças relacionadas com eosinófilos, tais como síndrome de Churg-Strauss e sinusite; doenças relacionadas com basófilos, tais como leucemia basofilica, urticária crónica e leucocitose basofílica em humanos e outros mamíferos; e doenças inflamatórias, caracterizadas por linfócitos T e infiltrados de leucócitos profusos, tais como psoríase, eczema, doença inflamatória dos intestinos, colite ulcerativa, doença de Crohn, COPD (distúrbio pulmonar obstrutivo crónico) e artrite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03009384A EP1471057B1 (en) | 2003-04-25 | 2003-04-25 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 |
| PCT/EP2004/003910 WO2004096777A1 (en) | 2003-04-25 | 2004-04-14 | Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409733A true BRPI0409733A (pt) | 2006-05-09 |
Family
ID=32946880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409733-5A BRPI0409733A (pt) | 2003-04-25 | 2004-04-14 | derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animais |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7812160B2 (pt) |
| EP (2) | EP1471057B1 (pt) |
| JP (2) | JP4671955B2 (pt) |
| KR (1) | KR101110491B1 (pt) |
| CN (2) | CN101914065A (pt) |
| AR (1) | AR043885A1 (pt) |
| AT (2) | ATE316077T1 (pt) |
| AU (1) | AU2004233966B2 (pt) |
| BR (1) | BRPI0409733A (pt) |
| CA (1) | CA2523439C (pt) |
| CL (1) | CL43596B (pt) |
| CY (1) | CY1111295T1 (pt) |
| DE (2) | DE60303238T2 (pt) |
| DK (2) | DK1471057T3 (pt) |
| DO (1) | DOP2004000875A (pt) |
| ES (2) | ES2257616T3 (pt) |
| GT (1) | GT200400079A (pt) |
| HN (1) | HN2004000129A (pt) |
| IL (1) | IL171566A (pt) |
| MX (1) | MXPA05011399A (pt) |
| MY (1) | MY147984A (pt) |
| NO (1) | NO20055588L (pt) |
| NZ (1) | NZ543693A (pt) |
| PE (1) | PE20050143A1 (pt) |
| PL (1) | PL1633726T3 (pt) |
| PT (2) | PT1471057E (pt) |
| RU (1) | RU2361865C2 (pt) |
| SI (1) | SI1633726T1 (pt) |
| TW (1) | TWI353980B (pt) |
| UY (1) | UY28286A1 (pt) |
| WO (1) | WO2004096777A1 (pt) |
| ZA (1) | ZA200508722B (pt) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| ATE316077T1 (de) | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| PT2805728T (pt) * | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
| ATE433452T1 (de) * | 2004-01-31 | 2009-06-15 | Actimis Pharmaceuticals Inc | Imidazoä1,2-cüpyrimidinylessigsäurederivate |
| NZ550365A (en) | 2004-03-11 | 2010-09-30 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
| EP1871374B1 (en) | 2005-04-21 | 2011-09-14 | Merck Serono SA | 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 |
| ATE529429T1 (de) | 2005-05-24 | 2011-11-15 | Merck Serono Sa | Tricyclische spiroderivate als crth2-modulatoren |
| AR056871A1 (es) * | 2005-10-04 | 2007-10-31 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| JP5155171B2 (ja) * | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| WO2007062677A1 (en) * | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| CA2654784A1 (en) * | 2006-06-09 | 2007-12-13 | Icos Corporation | Substituted phenylacetic acids as dp-2 antagonists |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| RU2468013C2 (ru) * | 2007-06-21 | 2012-11-27 | Актимис Фармасьютикалз, Инк. | Аминовые соли антагониста crth2 |
| US8507005B2 (en) * | 2007-06-21 | 2013-08-13 | Actimis Pharmaceuticals, Inc. | Particulates of a CRTH2 antagonist |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| AU2008305632B2 (en) | 2007-09-25 | 2014-01-30 | Actimis Pharmaceuticals, Inc. | Alkylthio pyrimidines as CRTH2 antagonists |
| BRPI0817318A2 (pt) * | 2007-09-25 | 2015-03-17 | Actimis Pharmaceuticals Inc | Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma. |
| MX2010008260A (es) | 2008-02-01 | 2010-12-20 | Amira Pharmaceuticals Inc | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina. |
| US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
| WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
| EP2268611A2 (en) | 2008-04-02 | 2011-01-05 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| JP5531370B2 (ja) | 2008-07-03 | 2014-06-25 | パンミラ ファーマシューティカルズ，エルエルシー． | プロスタグランジンｄ２受容体のアンタゴニスト |
| US8541419B2 (en) | 2008-09-02 | 2013-09-24 | Actimis Pharmaceuticals, Inc. | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| CA2747795A1 (en) * | 2008-12-25 | 2010-07-01 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
| JP2012517405A (ja) * | 2009-02-09 | 2012-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器及び胃腸の疾患の治療のための新規医薬組成物 |
| US8273769B2 (en) | 2009-02-12 | 2012-09-25 | Merck Serono Sa | Phenoxy acetic acid derivatives |
| WO2010094643A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2768492A1 (en) | 2009-07-31 | 2011-02-03 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| GB0913636D0 (en) * | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2781610A1 (en) * | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative |
| KR20120115989A (ko) | 2010-01-06 | 2012-10-19 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| BR112012018695A2 (pt) | 2010-01-27 | 2016-04-12 | Boehringer Ingelheim Int | compostos pirazol como antagonistas crth2 |
| MX2012014667A (es) | 2010-06-23 | 2013-02-15 | Taisho Pharma Co Ltd | Derivado de isoquinolina. |
| TW201201805A (en) | 2010-07-05 | 2012-01-16 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| WO2012013566A1 (en) | 2010-07-28 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and inflammatory diseases |
| EP2598145A1 (en) * | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| MX346116B (es) | 2010-10-20 | 2017-03-08 | Valspar Sourcing Inc | Sistema de revestimiento a base de agua con adhesion mejorada a una amplia variedad de sustratos revestidos y sin revestir, incluido el acero inoxidable de grado silenciador. |
| MX2013005478A (es) | 2010-11-15 | 2013-08-29 | Univ Leuven Kath | Compuestos heterociclicos condensados antivirales. |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US8759386B2 (en) | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| US9206164B2 (en) | 2011-03-25 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| PL2709988T3 (pl) * | 2011-05-16 | 2018-04-30 | Actimis Pharmaceuticals, Inc. | Proces przygotowania kwasu [4,6-bis-dimetyloamino-2-[4-(4- trifluorometylbenzoyl-amino)benzylo]pyrimidin-5-ylo] octowego |
| AU2012351342A1 (en) | 2011-12-16 | 2014-07-24 | Atopix Therapeutics Limited | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| EP2794563B1 (en) | 2011-12-21 | 2017-02-22 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| WO2014079806A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrimidine compounds for treating hairloss |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9125842D0 (en) * | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| US6326368B1 (en) * | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| CN1169791C (zh) * | 1996-09-06 | 2004-10-06 | 日本化药株式会社 | 新颖的乙酰胺衍生物和蛋白酶抑制剂 |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| RU2270194C2 (ru) * | 2000-05-22 | 2006-02-20 | Лео Фарма А/С | Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1413306A1 (en) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
| EA011087B1 (ru) | 2002-12-20 | 2008-12-30 | Эмджен Инк. | Соединения и фармацевтические композиции для лечения воспалительных заболеваний |
| ATE316077T1 (de) * | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| US8507005B2 (en) | 2007-06-21 | 2013-08-13 | Actimis Pharmaceuticals, Inc. | Particulates of a CRTH2 antagonist |
| RU2468013C2 (ru) | 2007-06-21 | 2012-11-27 | Актимис Фармасьютикалз, Инк. | Аминовые соли антагониста crth2 |
-
2003
- 2003-04-25 AT AT03009384T patent/ATE316077T1/de active
- 2003-04-25 PT PT03009384T patent/PT1471057E/pt unknown
- 2003-04-25 EP EP03009384A patent/EP1471057B1/en not_active Expired - Lifetime
- 2003-04-25 DK DK03009384T patent/DK1471057T3/da active
- 2003-04-25 DE DE60303238T patent/DE60303238T2/de not_active Expired - Lifetime
- 2003-04-25 ES ES03009384T patent/ES2257616T3/es not_active Expired - Lifetime
-
2004
- 2004-04-01 DO DO2004000875A patent/DOP2004000875A/es unknown
- 2004-04-14 MX MXPA05011399A patent/MXPA05011399A/es active IP Right Grant
- 2004-04-14 CA CA2523439A patent/CA2523439C/en not_active Expired - Fee Related
- 2004-04-14 PL PL04727274T patent/PL1633726T3/pl unknown
- 2004-04-14 CN CN2010101716294A patent/CN101914065A/zh active Pending
- 2004-04-14 JP JP2006505114A patent/JP4671955B2/ja not_active Expired - Fee Related
- 2004-04-14 ES ES04727274T patent/ES2358424T3/es not_active Expired - Lifetime
- 2004-04-14 RU RU2005136655/04A patent/RU2361865C2/ru not_active IP Right Cessation
- 2004-04-14 DE DE602004030907T patent/DE602004030907D1/de not_active Expired - Lifetime
- 2004-04-14 NZ NZ543693A patent/NZ543693A/en not_active IP Right Cessation
- 2004-04-14 KR KR1020057020304A patent/KR101110491B1/ko not_active Expired - Fee Related
- 2004-04-14 CN CN2004800173378A patent/CN1809539B/zh not_active Expired - Fee Related
- 2004-04-14 SI SI200431585T patent/SI1633726T1/sl unknown
- 2004-04-14 AT AT04727274T patent/ATE494279T1/de active
- 2004-04-14 EP EP04727274A patent/EP1633726B1/en not_active Expired - Lifetime
- 2004-04-14 BR BRPI0409733-5A patent/BRPI0409733A/pt not_active IP Right Cessation
- 2004-04-14 WO PCT/EP2004/003910 patent/WO2004096777A1/en not_active Ceased
- 2004-04-14 PT PT04727274T patent/PT1633726E/pt unknown
- 2004-04-14 DK DK04727274.5T patent/DK1633726T3/da active
- 2004-04-14 AU AU2004233966A patent/AU2004233966B2/en not_active Ceased
- 2004-04-14 US US10/554,668 patent/US7812160B2/en not_active Expired - Fee Related
- 2004-04-14 ZA ZA200508722A patent/ZA200508722B/en unknown
- 2004-04-19 AR ARP040101311A patent/AR043885A1/es not_active Application Discontinuation
- 2004-04-21 HN HN2004000129A patent/HN2004000129A/es unknown
- 2004-04-21 GT GT200400079A patent/GT200400079A/es unknown
- 2004-04-22 MY MYPI20041479A patent/MY147984A/en unknown
- 2004-04-23 CL CL200400874A patent/CL43596B/es active
- 2004-04-23 PE PE2004000402A patent/PE20050143A1/es not_active Application Discontinuation
- 2004-04-23 UY UY28286A patent/UY28286A1/es not_active Application Discontinuation
- 2004-04-23 TW TW093111323A patent/TWI353980B/zh not_active IP Right Cessation
-
2005
- 2005-10-26 IL IL171566A patent/IL171566A/en not_active IP Right Cessation
- 2005-11-25 NO NO20055588A patent/NO20055588L/no not_active Application Discontinuation
-
2010
- 2010-08-25 US US12/868,663 patent/US7960393B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249273A patent/JP5161290B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-03 CY CY20111100113T patent/CY1111295T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0409733A (pt) | derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animais | |
| BRPI0507123A (pt) | composto, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associadas com a atividade de crth2 no ser humano e animais | |
| BR0314830A (pt) | Derivados de azol-pirimidina fundida | |
| AU2016372028B2 (en) | Methods of treating hyperalgesia | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112017010261A2 (pt) | composto, composição farmacêutica, e, método de tratamento para tratar distúrbios do sistema nervoso central (cns). | |
| BR0313460A (pt) | Derivados de naftaleno como inibidores de metaloproteinase da matriz | |
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| BR112014032581A2 (pt) | inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune | |
| BR112021009078A8 (pt) | Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos | |
| BR112014013958A8 (pt) | ácidos piperidinila naftilacéticos | |
| BR112021006423A2 (pt) | derivados de azitromicina e roxitromicina como fármacos senolíticos | |
| CO2021007721A2 (es) | Proceso farmacéutico e intermedios | |
| BRPI0911678B8 (pt) | maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central | |
| WO2017193872A1 (en) | Certain protein kinase inhibitors | |
| SUzUkI et al. | Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks | |
| Naik et al. | Modulation of inflammasome activity for the treatment of auto-inflammatory disorders | |
| KR20220127824A (ko) | 알파1-항트립신 결핍의 치료를 위한 4-((2-옥소피리딘-1(2h)-일)메틸)벤즈아미드 | |
| US20220313681A1 (en) | Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases | |
| US20230210837A1 (en) | Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases | |
| Xia et al. | Substituted dipiperidine alcohols as potent CCR2 antagonists | |
| BR0011296A (pt) | Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos | |
| Ciruela et al. | Adenosine in the neurobiology of schizophrenia: potential adenosine receptor-based pharmacotherapy | |
| CO2026000808A2 (es) | Derivados de 2-fenoxi-1-(4-(alquilsulfonil)piperidin-1-il)etan-1-ona y 3-fenil-1-(4-alquilsulfonil)piperidin-1-il)prop-2-en-1-ona como antagonistas de gpr183 para el tratamiento de dolor crónico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015. |